▎ WuXi AppTec content team editor
Recently, Retro Biosciences stepped out of the hidden mode and announced the completion of a $180 million financing. The company's official website points out that Retro's goal is to extend the healthy life of humans by 10 years! The funding from this round of funding will support the company in completing the proof of concept.
Globally, a lot of medical health spending is spent treating age-related diseases, and the reason behind age-related diseases is the aging process itself. By focusing on the cellular drivers of aging, Retro is committed to developing innovative therapies that ultimately prevent a wide range of diseases.
The company's initial focus areas include cell reprogramming, plasma-related therapies, and autophagy. A molecule from the company's autophagy research and development program is expected to enter the clinical development phase next year. In addition, the company is exploring and optimizing plasma therapies in preclinical and clinical settings, and expects to identify the first candidate therapies within two years. Cell reprogramming research is expected to move towards a clinical proof of concept over the next four years. To support three research directions, the company will focus on investing in single-cell multi-omics, machine learning-based computational biology, and laboratory automation.
Image credit: 123RF
The company's co-founders include serial entrepreneur Dr. Joe Betts-LaCroix, Professor Sheng Ding of Tsinghua University's School of Pharmacy, and Dr. Matt Buckley.
Resources:
[1] Announcing Retro Biosciences. Retrieved April 6, 2022, from https://retro.bio/announcement/
Disclaimer: WuXi AppTec's content team focuses on the global biomedical health research process. This article is for informational purposes only and the views expressed herein do not represent the position of WuXi AppTec, nor do they represent WuXi AppTec's support for or opposition to the views expressed herein. This article is also not recommended for treatment options. For guidance on treatment options, please visit a regular hospital.
Copyright note: This article is from WuXi AppTec content team, welcome to forward to the circle of friends, refuse the media or institutions to reprint to other platforms in any form without authorization. Reprint authorization, please reply to "Reprint" on the "WuXi AppTec" WeChat public account to obtain the reprint instructions.
Share, like, watch, focus on global biomedical health innovation